Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1963 1
1964 1
1966 1
1967 6
1968 6
1969 6
1970 5
1971 9
1972 8
1973 4
1974 10
1975 7
1976 4
1977 13
1978 7
1979 10
1980 6
1981 4
1982 12
1983 4
1984 5
1985 10
1986 8
1987 11
1988 2
1989 5
1990 8
1991 8
1992 6
1993 11
1994 7
1995 4
1996 7
1997 2
1998 2
1999 4
2000 1
2001 5
2002 2
2003 4
2004 2
2005 1
2006 2
2007 1
2008 1
2009 2
2011 1
2012 1
2013 1
2014 1
2015 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Results by year

Filters applied: . Clear all
Page 1
Suppression of normal hematopoiesis during acute leukemias.
Najman A, Kobari L, Khoury E, Baillou CL, Lemoine F, Guigon M. Najman A, et al. Ann N Y Acad Sci. 1991;628:140-7. doi: 10.1111/j.1749-6632.1991.tb17231.x. Ann N Y Acad Sci. 1991. PMID: 2069293 Review. No abstract available.
Intrathecal mitozantrone.
Laporte JP, Godefroy W, Verny A, Gorin NC, Najman A, Duhamel G. Laporte JP, et al. Among authors: najman a. Lancet. 1985 Jul 20;2(8447):160. doi: 10.1016/s0140-6736(85)90268-5. Lancet. 1985. PMID: 2862355 No abstract available.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: najman a. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms.
Rabadan Moraes G, Pasquier F, Marzac C, Deconinck E, Damanti CC, Leroy G, El-Khoury M, El Nemer W, Kiladjian JJ, Raslova H, Najman A, Vainchenker W, Marty C, Bellanné-Chantelot C, Plo I. Rabadan Moraes G, et al. Among authors: najman a. Br J Haematol. 2022 Jul;198(1):131-136. doi: 10.1111/bjh.18165. Epub 2022 Mar 30. Br J Haematol. 2022. PMID: 35355248
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
Pegliasco J, Hirsch P, Marzac C, Isnard F, Meniane JC, Deswarte C, Pellet P, Lemaitre C, Leroy G, Rabadan Moraes G, Guermouche H, Schmaltz-Panneau B, Pasquier F, Colas C, Benusiglio PR, Bera O, Bourhis JH, Brissot E, Caron O, Chraibi S, Cony-Makhoul P, Delaunay-Darivon C, Lapusan S, de Fontbrune FS, Fuseau P, Najman A, Vainchenker W, Delhommeau F, Micol JB, Plo I, Bellanné-Chantelot C. Pegliasco J, et al. Among authors: najman a. Leukemia. 2022 Jan;36(1):126-137. doi: 10.1038/s41375-021-01319-w. Epub 2021 Jun 25. Leukemia. 2022. PMID: 34172895
Human liquid bone marrow culture in serum-free medium.
Drouet X, Douay L, Giarratana MC, Baillou C, Gorin NC, Salmon C, Najman A. Drouet X, et al. Among authors: najman a. Br J Haematol. 1989 Oct;73(2):143-7. doi: 10.1111/j.1365-2141.1989.tb00243.x. Br J Haematol. 1989. PMID: 2818936
252 results